Market closedNon-fractional

Cytosorbents/CTSO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Cytosorbents

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Ticker

CTSO

Sector

Healthcare

Trading on

NASDAQ

Industry

Health Care Equipment and Supplies

Headquarters

Princeton, United States

Employees

186

Cytosorbents Metrics

BasicAdvanced
$49M
Market cap
-
P/E ratio
-$0.58
EPS
0.62
Beta
-
Dividend rate
$49M
0.62
1.489
1.145
77.763
93.047
-269.37%
-32.65%
-115.03%
1.172
2.62
2.62
-1.81
3.50%
-18.08%
-5.08%
40.76%

What the Analysts think about Cytosorbents

Analyst Ratings

Majority rating from 2 analysts.
Buy

Cytosorbents Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-64.94% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.7M
12.79%
Net income
-$6.3M
8.62%
Profit margin
-64.94%
-3.71%

Cytosorbents Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.00%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.14
-$0.21
-$0.13
-$0.12
-
Expected
-$0.11
-$0.14
-$0.14
-$0.12
-$0.09
Surprise
24.44%
52.17%
-5.45%
0.00%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cytosorbents stock?

Cytosorbents (CTSO) has a market cap of $49M as of July 06, 2024.

What is the P/E ratio for Cytosorbents stock?

The price to earnings (P/E) ratio for Cytosorbents (CTSO) stock is 0 as of July 06, 2024.

Does Cytosorbents stock pay dividends?

No, Cytosorbents (CTSO) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Cytosorbents dividend payment date?

Cytosorbents (CTSO) stock does not pay dividends to its shareholders.

What is the beta indicator for Cytosorbents?

Cytosorbents (CTSO) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Cytosorbents stock

Buy or sell Cytosorbents stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing